Loading
A phase 3 trial testing Rondecabtagene autoleucel in diffuse large B-cell lymphoma and hodgkin lymphoma, now recruiting.
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy is a phase 3 interventional study registered as NCT07188558, led by Lyell Immunopharma, and recruiting on the registry. Official title: A Phase 3 Randomised Controlled Trial of Rondecabtagene Autoleucel, an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting. Planned enrolment is 400 participants (estimated). The study started in 2026-01-12 and primary completion is expected in 2029-12. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/